GHRP-2
GHRP-2 (Pralmorelin)
Potent Ghrelin Receptor Agonist for Growth Hormone Stimulation
What is GHRP-2?
GHRP-2 (Growth Hormone Releasing Peptide-2), also known by its pharmaceutical name pralmorelin, is a synthetic hexapeptide that acts as a potent agonist at the ghrelin receptor (GHS-R1a), triggering robust secretion of growth hormone (GH) from the anterior pituitary. Among the growth hormone secretagogue peptides, GHRP-2 is notable for producing some of the highest GH pulse amplitudes per unit dose of any compound in its class, while being somewhat more favorable than GHRP-6 in terms of appetite stimulation, though this effect is still present.
GHRP-2 operates through a receptor and signaling pathway that is distinct from that of growth hormone-releasing hormone (GHRH). Both GHRH and GHRP-2 stimulate GH release, but through different receptor systems that converge at the pituitary level. This complementary mechanism creates a synergistic interaction: when GHRP-2 is co-administered with a GHRH analog such as CJC-1295, the resulting GH pulse is significantly larger than either compound produces alone. Clinical research published in The Journal of Clinical Endocrinology and Metabolism confirmed that GHRP-2 administration acutely increases plasma GH levels, with peak GH concentrations occurring approximately 60 minutes post-injection and returning to baseline within three hours.
Research in humans and animal models has examined GHRP-2 in the context of growth hormone deficiency, short stature in children, and body composition modification. A pediatric study used intranasal GHRP-2 at 5 to 15 micrograms per kilogram, administered two to three times daily over three months, and found measurable improvements in growth velocity. GHRP-2 also increases food intake acutely through the same ghrelin pathway, though this effect is less pronounced than with GHRP-6.
GHRP-2 has not been approved by the FDA for human therapeutic use. It is available as a research compound and is studied in controlled settings. Clinical data supporting its use in healthy adult populations for body composition or anti-aging purposes remains limited.
Research Supply
Source high-purity GHRP-2 for your research
Dosage Guide
Route: Subcutaneous injection, in a fasted state or at minimum two hours after eating
Dosing Schedule
| Period | Dose |
|---|---|
| Entry level | 100 mcg, 2x daily (morning fasted + bedtime) |
| Standard research | 100-200 mcg, 2-3x daily |
| High dose | 300 mcg, 2-3x daily (diminishing returns above 300 mcg) |
| Pediatric (intranasal, study) | 5-15 mcg/kg, 2-3x daily (clinical research protocol only) |
| Combined with GHRH analog | 100 mcg GHRP-2 + 100 mcg CJC-1295, 2x daily |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|---|---|
| 100 mcg | 0.05 mL | 5 units |
| 200 mcg | 0.10 mL | 10 units |
| 300 mcg | 0.15 mL | 15 units |
Cycling Protocol
8-12 weeks
4-8 weeks
Off periods help preserve GHS-R1a receptor sensitivity and maintain GH pulse amplitude
Administration Tips
- Inject in a fasted state -- elevated blood glucose or insulin significantly reduces GH release
- GH levels typically peak at 60 minutes post-injection and normalize within three hours
- The feedback mechanisms governing endogenous GH secretion remain partially intact with GHRP-2, providing some protection against runaway GH elevation
- Store reconstituted solution refrigerated and use within 30 days
- Keep unreconstituted lyophilized powder frozen until ready to use
- Combine with a GHRH analog for synergistic GH amplification if desired
Risks & Side Effects
Commonly Reported
Serious Risks
Promotion of tumor growth
Elevated GH and IGF-1 are potent mitogenic signals. Individuals with active or prior malignancy should not use GH secretagogues.
Pituitary desensitization
Continuous high-frequency use can desensitize the GHS-R1a receptor, diminishing GH response over time.
Carpal tunnel syndrome
Prolonged elevated IGF-1 can cause progressive carpal tunnel syndrome requiring intervention.
Contraindications
- Active or history of malignancy
- Diabetic individuals or those with clinically impaired glucose tolerance
- Pregnancy and lactation
- Active acromegaly
- Pediatric use without physician oversight (open growth plates)
- Known hypersensitivity to the compound or formulation components
Frequently Asked Questions
Related Peptides
Experts Covering GHRP-2
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. GHRP-2 has not been approved by the FDA for any medical condition. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.